ANNX at a glance
Annexon, Inc. (ANNX, SEC CIK 1528115) filed its latest 10-K annual report on March 30, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on August 12, 2026 and Form 4 insider filings as recently as September 25, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Annexon, Inc. (ANNX) shares worth $427.7 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Love Douglas on September 24, 2026 of 26,065 shares at $3.83 per share.
- In the last 90 days, ANNX insiders reported 1 open-market purchase ($100K) and 0 open-market sales ($0) on Form 4, a net purchase of $100K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 1 buy · 0 sells
- Net +$100K
- 13F holders
- 28 funds
- $427.7M · +0 vs prior quarter
- Latest 8-K
- Aug 12, 2026
- Item 8.01 · Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- New debt risk triggered by July 30, 2026 Loan Agreement: $50 million funded, floating interest rate at least 7.60%
- Financial flexibility constrained by debt secured against substantially all assets and potential acceleration upon default
- Phase 3 ARCHER II regulatory risk: FDA may reject global trial data despite established U.S. and European registration path
- Near-term execution risk from expensive, multi-jurisdictional ARCHER II trial potentially delaying vonaprument development
- Liquidity risk with $209.2 million resources funding planned expenses into 2028 and additional capital needs possible sooner
AI summary of the ANNX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Annexon expanded vonaprument’s Phase 3 geographic atrophy program with a Month 24 dual primary endpoint
- Month 24 endpoint complements the existing Month 15 primary endpoint
Item 2.02: Results of Operations and Financial Condition
- Exhibit 99.1 excluded from incorporation by reference into future SEC filings
- Section provides no earnings figures or operating results; investor-relevant details require review of Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 net loss $55.3M, or $0.28 per share, versus $49.2M and $0.34 in Q2 2025
- Cash, equivalents and short-term investments $209.2M at June 30, with runway expected into 2028
Item 7.01: Regulation FD Disclosure
- Board transition: Mr. Satter resigned and Dr. Blumenkranz was appointed
- Governance change may affect strategic oversight and investor confidence
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Muneer Satter resigned immediately before successor appointment after more than 11 years, with no operational, policy, or strategy disagreement
- Mark S. Blumenkranz appointed Class II director through 2028 annual meeting, adding ophthalmology expertise to the Board
Item EX-99.1: Item EX-99.1
- Board adds Mark S. Blumenkranz, retinal specialist and biotechnology entrepreneur with over four decades of industry experience
- Appointment strengthens strategic expertise for vonaprument’s geographic atrophy program and potential commercialization
Item 8.01: Other Events
- ANN-EXON’s GBS FORWARD study reported rapid positive clinical responses in all tanruprubart-treated patients within one week
- Results cover the first U.S. and European patient cohort, supporting early clinical activity in Guillain-Barré syndrome
Item EX-99.1: Item EX-99.1
- FORWARD initial cohort showed rapid strength improvement in all 10 patients within four days after one 30 mg/kg infusion
- Four bedbound patients walked by days 2–8; the sole ventilated patient discontinued ventilation within four days
AI summaries of ANNX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ANNX
Don't miss the next ANNX filing
- Alerts as it files. A push when ANNX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ANNX, by share count.
- Ask anything. An AI agent that reads every ANNX filing and answers with sources.
ANNX alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Love Douglas | Buy | Sep 24, 2026 | 26,065 | $3.83 |
| Blumenkranz Mark S. | A | Aug 10, 2026 | 175,000 | - |
| Yednock Ted | M | Jun 11, 2026 | 30,646 | - |
| Waddill William D. | A | Jun 11, 2026 | 65,000 | - |
| JONES WILLIAM A JR | A | Jun 11, 2026 | 65,000 | - |
| Choi Jung | A | Jun 11, 2026 | 65,000 | - |
| Carson William H. | A | Jun 11, 2026 | 65,000 | - |
| Satter Muneer A | A | Jun 11, 2026 | 65,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$143.7M | -$154.1M | -$216.4M |
| Net Income | - | -$138.2M | -$206.7M |
| Balance Sheet | |||
| Total Assets | $297.7M | $350.1M | $277.6M |
| Equity | $250.6M | $293.1M | $211.6M |
| ROE | - | -47.2% | -97.7% |
| Per Share | |||
| EPS | $-1.77 | $-1.01 | $-1.34 |
| Cash Flow | |||
| Operating CF | -$121.1M | -$118.0M | -$186.4M |
| CapEx | $193K | $15K | $137K |
Source: XBRL data in Annexon, Inc. (ANNX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ANNX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 28 | $427.7M |
| Q1 2026 | 28 | $318.9M |
| Q4 2025 | 25 | $262.8M |
| Q3 2025 | 25 | $133.0M |
| Q2 2025 | 24 | $105.8M |
| Q1 2025 | 20 | $63.7M |
| Q4 2024 | 17 | $150.1M |
| Q3 2024 | 16 | $44.2M |
- FMR LLC (Fidelity)+8.88M (+84%)
- Goldman Sachs Group+3.67M (+171%)
- State Street Corp+2.91M (+42%)
- BlackRock+2.60M (+24%)
- Vanguard Capital Management LLC+914.4K (+15%)
- Bank of America Corp−3.65M (-86%)
- D.E. Shaw & Co−437.5K (-62%)
- Invesco Ltd−432.3K (-57%)
- T. Rowe Price Group−299.5K (-70%)
- AQR Capital Management−85.4K (-11%)
- U.S. Bancorp−77
Source: 13F-HR filings on SEC EDGAR (aggregated from 183 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ANNX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 10-Q | Aug 12, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| SC 13G | Aug 7, 2026 | - | - | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 8-K | Jun 12, 2026 | - | Analysis | - |
| 4 | May 29, 2026 | - | - | |
| 4 | May 13, 2026 | - | - | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 4 | Apr 14, 2026 | - | - | - |
| 8-K | Mar 30, 2026 | - | - | - |
| 10-K | Mar 30, 2026 | Dec 31, 2025 | - | |
| 4 | Mar 12, 2026 | - | - | - |
| 4 | Mar 4, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ANNX SEC filings: frequently asked questions
Are ANNX insiders buying or selling?
In the last 90 days, Annexon, Inc. (ANNX) officers, directors and 10% owners reported 1 open-market purchase worth $99,829 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ANNX stock?
As of June 30, 2026, the largest Annexon, Inc. (ANNX) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($111.5 million), BlackRock ($77.3 million), State Street Corp ($56.1 million), Vanguard Capital Management LLC ($39.2 million), Goldman Sachs Group ($33.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did ANNX report in its latest 8-K?
Annexon, Inc. (ANNX) filed an 8-K on August 12, 2026 reporting Item 8.01 (Other Events) and Item 2.02 (Results of Operations and Financial Condition). Annexon expanded vonaprument’s Phase 3 geographic atrophy program with a Month 24 dual primary endpoint.
What are the latest ANNX SEC filings?
Annexon, Inc. (ANNX) filed its latest 10-K annual report on March 30, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on August 12, 2026 and a Form 4 insider filing on September 25, 2026.
What is ANNX's SEC CIK number?
Annexon, Inc. (ANNX)'s SEC Central Index Key (CIK) is 1528115. EDGAR lists every ANNX filing under that number.
Ask anything about ANNX
The research agent reads ANNX's filings, financials, insider trades and 13F holders, then answers with sources.